Specifically, both BNP and NT-proBNP are utilized as indicators of the progression and prognosis of CHF and guiding standardized treatment; however, N-terminal peptides are more frequently measured for research and clinical diagnostics due to their longer half-lives (7). This evidence concerns the gene NPPB and congestive heart failure.